This is a routine IP update for a micro-cap biotech with a $4M market cap and no disclosed revenue. The patent publication and FDA guidance are incremental positives for the long-term pipeline but do not change the near-term financial outlook. Monitor for any subsequent clinical trial initiation or partnership funding announcements from NeuroThera.
Price Chart
Executive Summary
SciSparc announced via press release that its subsidiary NeuroThera's collaboration with Clearmind Medicine has achieved a U.S. patent publication covering an MDMA-PEA combination for PTSD, anxiety, and eating disorders. The filing also highlights the FDA's final guidance on psychedelic drug development, which explicitly includes MDMA. This is a non-financial, early-stage IP milestone for a micro-cap biotech with no revenue or clinical data disclosed, making the near-term stock impact negligible.
Key Facts
- NeuroThera-Clearmind collaboration published a U.S. patent application for MDMA-PEA combination treating PTSD, anxiety, and eating disorders.
- The collaboration has generated 13 published patent applications globally.
- FDA finalized guidance 'Psychedelic Drugs: Considerations for Clinical Investigations' on July 14, 2026, explicitly including MDMA.
- No financial terms, clinical trial data, or revenue figures were disclosed in the filing.
Financial Impact
No financial figures disclosed; early-stage IP milestone with no revenue or clinical data.
Risk Factors
- No disclosed clinical data or revenue to support valuation.
- Micro-cap biotech with high dilution risk and limited cash runway.
- Forward-looking statements about therapeutic potential are speculative and unvalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-092838 |
| Document: 0001213900-26-092838-index-headers.html | 0001213900-26-092838 |
| Document: 0001213900-26-092838-index.html | 0001213900-26-092838 |
| Document: 0001213900-26-092838.txt | 0001213900-26-092838 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers